TORONTO and HAIFA, Israel, Oct. 30, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) today announced new laboratory results demonstrating consistent anti-inflammatory activity across three batches of its naïve exosomes, supporting both its developing commercial supply business through Exo-Top Inc. (“Exo-Top”) and continued development of its lead therapeutic candidate, ExoPTEN.
Anti-inflammatory activity is a key biological property attracting interest in exosomes for applications ranging from skin health to tissue repair. NurExone’s latest results showed that three separately produced batches demonstrated similar and substantial anti-inflammatory activity. Two key proteins involved in inflammation, IL-6 and TNF-α, showed average reductions of approximately 88% and 57%, respectively. This anti-inflammatory activity shown in the laboratory supports the potential of NurExone’s exosomes for clinical applications where controlling inflammation is relevant to tissue protection, repair and regeneration.
“The anti-inflammatory properties of our exosomes have potential relevance for both our therapeutic development and commercial strategy,” said Dr. Lior Shaltiel, Chief Executive Officer of NurExone. “For ExoPTEN, these findings support the exosome component of our approach to acute spinal cord and optic nerve injuries. For Exo-Top, they provide additional evidence of product consistency as we begin manufacturing and work toward supplying naïve exosomes for applications such as skin and tissue care. Addressing batch-to-batch consistency, a critical unmet challenge in the exosome field, helps distinguish the quality and reliability we expect to bring to the exosome market.”